Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A $63m VC Round Takes E-Scape Into Clinic With Alzheimer's, Parkinson's Drugs

Executive Summary

E-Scape's Series A cash will fund the development of small molecules targeting genetic drivers of neurodegenerative diseases, such as ApoE4 in Alzheimer's disease. The venture capital financing with big pharma backing will be used to take two programs into the clinic.

Advertisement

Related Content

Accera Posts Phase III Alzheimer's Failure, But Moves Ahead With New Formulation
After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
Alzheon's Reclaimed Alzheimer's Drug Has Potential To Win Big – If History Doesn't Repeat
10 Things You Want To Know About Alzheimer's Drug Research
Alzheimer's Disease: Learning the Lessons Of The Past To Prepare For The Future

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel